HOME > TOP STORIES

TOP STORIES

ORGANIZATION JPWA Board of Directors Approve By-Category Talks to Be Common Understanding

January 27, 2012
REGULATORY Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness

January 26, 2012
REGULATORY 16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion

January 25, 2012
BUSINESS Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs

January 24, 2012
BUSINESS Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System

January 23, 2012
REGULATORY PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis

January 20, 2012
BUSINESS Takeda President Hasegawa Envisions Japanese National as Successor

January 19, 2012
BUSINESS Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey

January 18, 2012
ORGANIZATION JPWA, NPhA Hold Talks for Distribution Improvement

January 18, 2012
REGULATORY US Industry Opinion Divided on Japan’s Participation in TPP Talks

January 17, 2012
REGULATORY MHLW Proposes New Fee for Medical Management of Treatment-Resistant Schizophrenia

January 16, 2012
ORGANIZATION JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand

January 13, 2012
ORGANIZATION JPWA President Bessho Expresses Resolve for Distribution Improvement

January 12, 2012
BUSINESS Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field

January 11, 2012
BUSINESS Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus

January 10, 2012
BUSINESS AZ to Utilize E-detailing, Optimize According to Product

January 6, 2012
ORGANIZATION FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule

January 5, 2012
ORGANIZATION New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.

January 5, 2012
BUSINESS Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales

December 28, 2011
REGULATORY Additional NHI Price Cuts Decided: ¥22.5 Billion for Long-Listed Drugs, ¥2.5 Billion for Generics

December 27, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…